['neoplasms']
['caffeine', 'warfarin', 'omeprazole', 'midazolam', 'digoxin', 'vitamin k', 'rucaparib']

        Inclusion Criteria:

          -  Histologically or cytologically confirmed advanced solid tumor

          -  Have evidence of measurable disease as defined by RECIST Version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate bone marrow, renal, and liver function

        Exclusion Criteria:

          -  Prior treatment with chemotherapy, radiation, antibody therapy or other immunotherapy,
             gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental drugs within
             14 days prior to Day 1

          -  Prior treatment with any poly adenosine diphosphate ribose polymerase inhibitor
             (PARPi)

          -  Arterial or venous thrombi (including cerebrovascular accident), myocardial
             infarction, admission for unstable angina, cardiac angioplasty, stenting or poorly
             controlled hypertension within the last 3 months prior to Screening;

          -  Pre-existing duodenal stent, recent or existing bowel obstruction, and/or any
             gastrointestinal disorder or defect that would, in the opinion of the Investigator,
             interfere with absorption of study drugs

          -  Current use of therapeutic anticoagulation (low molecular weight heparin, oral
             anticoagulant agents including acetylsalicylic acid),

          -  Current use of one of the probe drugs;

          -  Untreated or symptomatic central nervous system (CNS) metastases.

          -  Evidence or history of bleeding disorder

          -  Participation in another investigational drug trial within 30 days prior to Day 1 (or
             5 times the half-life of the drug, whichever is longer) or exposure to more than three
             new investigational agents within 12 months prior to Day 1;

          -  Acute illness within 14 days prior to Day 1 unless mild in severity and approved by
             the Investigator and Sponsor's medical representative

          -  Active second malignancy, i.e., patient known to have potentially fatal cancer present
             for which they may be (but not necessarily) currently receiving treatment.
      